Pharma Blog Watch

GSK Pricing Deals (Pharma's Cutting Edge)
An entry in this blog discusses GlaxoSmithKline's (GSK) new European pricing agreements, about which few details have been released, that could possibly allow for "near-automatic increases in reimbursed price based on demonstrated value."

"It's a clear departure from current reference-pricing schemes that set a price based on the perceived value of a drug (relative to its reference group) at the time of launch, with little room for value-based price changes thereafter."